FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.

GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

The New York-listed healthcare giant is keen to recoup the £1.2bn it paid to buy the supplier of the electronic patient ...

The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings ...

A recent study shows adults with cardiovascular disease (CVD) have a higher risk of developing shingles. People who have two ...

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has announced the purchase of 248,000 of its own ordinary shares as part ...

A pharmaceutical factory which ceased production earlier this year has been bought by Britain's biggest defence firm. BAE ...

Dalhousie University, in collaboration with Nova Scotia Health's INSPIRED COPD Outreach Program, the Nova Scotia Health ...

GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK announced that the European Medicine Agency’s Committee for ...